Interim Report for the Period 1. January 2022 – 30. June 2022

29 September 2022 - 10:00

Company Announcement

Thursday, September 29, 2022, 10:00 CET

Brain+ A/S (“Brain+”) [BRAINP], today publishes the Interim Report for the Period 1. January 2022 – 30. June 2022

The interim report for the period 1. January 2022 – 30. June 2022 is available as an attached file and can also be read on the Company’s website at

Contact Information

CEO, Kim Baden-Kristensen + 45 31393317, E-mail: [email protected], Brain+ A/S, Købmagergade 53, 3.

Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: [email protected]


The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through software-as-medicine applications. Brain+ has developed a set of software-as-medicine technologies, which enable the Company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, puts Brain+ in a strong position to grow towards a market leader position in the Digital Therapeutics (DTx) space.

Provided by: Cision
Nasdaq First North GM Copenhagen (Denmark)
Brain+ A/S
Brain+ develops Digital Therapeutics for Alzheimer’s and dementia, presenting a unique opportunity to invest in a growing megatrend at the frontier of health care digitalisation....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More